Skip to content

Nalbuphine Hydrochloride

FDA-approved product (solution, intramuscular, intravenous, subcutaneous), marketed as Nalbuphine, Nalbuphine Hydrochloride, Nubain.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Nalbuphine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pain

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Morphinan derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nalbuphine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Serratus Anterior Plane Block Mastectomy

    NCT03944759 · start 2019-05-07

    Registered record
    Registry ID
    NCT03944759
    Conditions
    Postoperative Pain; Postoperative Complications
    Interventions
    serratus anterior plan block
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-05-07
    Completion
    2019-12-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain; Postoperative Complications
    Interventionserratus anterior plan block
    PhaseNot applicable
    Registry statusCompleted
  • The Effect of Analgesic Drugs on Respiratory Center

    NCT04372342 · start 2019-05-01

    Registered record
    Registry ID
    NCT04372342
    Conditions
    The Effect of Analgesic Drugs on Respiratory Center
    Interventions
    nalbuphine; remifentanil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-05-01
    Completion
    2021-12-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Effect of Analgesic Drugs on Respiratory Center
    Interventionnalbuphine; remifentanil
    PhasePhase 4
    Registry statusUnknown
  • Intravenous Lidocaine in Children Undergoing Laparoscopic Appendectomy

    NCT03886896 · start 2019-03-22

    Registered record
    Registry ID
    NCT03886896
    Conditions
    Acute Appendicitis; Postoperative Pain; Postoperative Nausea and Vomiting
    Interventions
    Lidocaine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-22
    Completion
    2020-01-17
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis; Postoperative Pain; Postoperative Nausea and Vomiting
    InterventionLidocaine
    PhasePhase 4
    Registry statusCompleted
  • Dexmedetomidine Versus Nalbuphine in Prevention of Emergence Agitation Following Adenotonsillectomy in Pediatrics

    NCT04058899 · start 2019-03-05

    Registered record
    Registry ID
    NCT04058899
    Conditions
    Emergence Delirium
    Interventions
    Dexmedetomidine; Nalbuphine; infusion pump
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2019-03-05
    Completion
    2019-09
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmergence Delirium
    InterventionDexmedetomidine; Nalbuphine; infusion pump
    PhasePhase 1 / Phase 2
    Registry statusUnknown
  • Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients

    NCT03825887 · start 2018-02-01

    Registered record
    Registry ID
    NCT03825887
    Conditions
    Acute Myeloid Leukemia; Stem Cell Leukemia
    Interventions
    Nalbuphine; Morphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-02-01
    Completion
    2020-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Stem Cell Leukemia
    InterventionNalbuphine; Morphine
    PhasePhase 3
    Registry statusCompleted
  • Pharmacokinetics of Nalbuphine Injection

    NCT03826316 · start 2018-01-15

    Registered record
    Registry ID
    NCT03826316
    Conditions
    Pain, Postoperative
    Interventions
    Nalbuphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-15
    Completion
    2019-01-15
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain, Postoperative
    InterventionNalbuphine
    PhasePhase 4
    Registry statusCompleted
  • Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery

    NCT03436836 · start 2018-01-14

    Registered record
    Registry ID
    NCT03436836
    Conditions
    Nalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery
    Interventions
    Nalbuphine; lidocaine, bupivacaine, hyaluronidase , saline; lidocaine, bupivacaine , hyaluronidase
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-01-14
    Completion
    2018-02-28
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery
    InterventionNalbuphine; lidocaine, bupivacaine, hyaluronidase , saline; lidocaine, bupivacaine , hyaluronidase
    PhaseNot applicable
    Registry statusCompleted
  • The Efficacy and Safety of NALDEBAIN for the Treatment of Post-Laparotomy Surgery

    NCT03296488 · start 2017-08-17

    Registered record
    Registry ID
    NCT03296488
    Conditions
    Pain, Postoperative
    Interventions
    Nalbuphine Sebacate; Fentanyl Citrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-08-17
    Completion
    2018-12-31
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain, Postoperative
    InterventionNalbuphine Sebacate; Fentanyl Citrate
    PhasePhase 4
    Registry statusUnknown
  • Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia

    NCT03131375 · start 2017-05-01

    Registered record
    Registry ID
    NCT03131375
    Conditions
    Emergence Delirium; Extubation Time; Heart Rate; Postoperative Analgesia; Blood Pressure
    Interventions
    Dexmedetomidine; Normal saline; Bispectral index; Train of four ratio
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2017-07-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmergence Delirium; Extubation Time; Heart Rate; Postoperative Analgesia +1 more
    InterventionDexmedetomidine; Normal saline; Bispectral index; Train of four ratio
    PhasePhase 2 / Phase 3
    Registry statusCompleted
  • Analgesia Comparison of Nalbuphine and Morphine for Laparoscopic Myomectomy

    NCT03288428 · start 2017-05-01

    Registered record
    Registry ID
    NCT03288428
    Conditions
    Postoperative Pain
    Interventions
    Nalbuphine; Morphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2018-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionNalbuphine; Morphine
    PhasePhase 4
    Registry statusCompleted
  • Morphine and/or Nalbuphine as Adjuvants in Ultrasound Guided Interscalene Block: for Shoulder Surgeries

    NCT03034382 · start 2016-01

    Registered record
    Registry ID
    NCT03034382
    Conditions
    Rotator Cuff Tear
    Interventions
    Morphine; Nalbuphine; Bupivacaine 0.5%; Lidocaine Hydrochloride 1% and epinephrine 1:400,000
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2017-06
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRotator Cuff Tear
    InterventionMorphine; Nalbuphine; Bupivacaine 0.5%; Lidocaine Hydrochloride 1% and epinephrine 1:400,000
    PhasePhase 2
    Registry statusUnknown
  • Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia

    NCT02678585 · start 2015-12

    Registered record
    Registry ID
    NCT02678585
    Conditions
    Postoperative Pain
    Interventions
    Nalbuphine; Lidocaine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-12
    Completion
    2016-03
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionNalbuphine; Lidocaine
    PhaseNot applicable
    Registry statusCompleted
  • Effect of Caudal Nalbuphine on Postoperative Analgesia in Children

    NCT02618876 · start 2015-11

    Registered record
    Registry ID
    NCT02618876
    Conditions
    Postoperative Pain
    Interventions
    Nalbuphine plus Bupivacaine; Bupivacaine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11
    Completion
    2019-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionNalbuphine plus Bupivacaine; Bupivacaine
    PhaseNot applicable
    Registry statusCompleted
  • Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

    NCT02174432 · start 2015-08-15

    Registered record
    Registry ID
    NCT02174432
    Conditions
    Prurigo Nodularis; Nodularis Prurigo; Prurigo
    Interventions
    nalbuphine HCl ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-08-15
    Completion
    2017-09-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrurigo Nodularis; Nodularis Prurigo; Prurigo
    Interventionnalbuphine HCl ER
    PhasePhase 2 / Phase 3
    Registry statusCompleted
  • A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy Volunteers

    NCT02446301 · start 2015-01

    Registered record
    Registry ID
    NCT02446301
    Conditions
    Pain; Analgesia Disorder
    Interventions
    Bain®; SDE
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-01
    Completion
    2015-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain; Analgesia Disorder
    InterventionBain®; SDE
    PhasePhase 1
    Registry statusCompleted